Unlike conventional therapeutics, immune checkpoint inhibitor (ICI) therapies that target PD-1, PD-L1, and CTLA4 have achieved positive outcomes in many CRC patient subgroups9–11. This evidence concerns the gene CTLA4 and colorectal carcinoma.